Morgan Stanley reiterated their overweight rating on shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in a research note released on Friday, The Fly reports. The brokerage currently has a $153.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $141.00.

A number of other equities analysts have also commented on the company. BidaskClub raised Alexion Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, July 25th. TheStreet raised Alexion Pharmaceuticals from a c rating to a b- rating in a research note on Friday, July 14th. SunTrust Banks, Inc. reaffirmed a buy rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, July 14th. Cowen and Company reaffirmed an outperform rating and issued a $122.00 price objective on shares of Alexion Pharmaceuticals in a research note on Monday, July 3rd. Finally, UBS AG reaffirmed a buy rating and issued a $142.00 price objective (up from $140.00) on shares of Alexion Pharmaceuticals in a research note on Monday, June 26th. Six analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the company. Alexion Pharmaceuticals has an average rating of Buy and an average target price of $156.85.

Shares of Alexion Pharmaceuticals (ALXN) opened at 138.18 on Friday. The company has a market capitalization of $30.84 billion, a PE ratio of 59.92 and a beta of 1.38. The stock has a 50 day moving average price of $124.34 and a 200-day moving average price of $122.55. Alexion Pharmaceuticals has a 52 week low of $96.18 and a 52 week high of $145.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.48. The company had revenue of $912 million for the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The firm’s quarterly revenue was up 21.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.13 earnings per share. Equities research analysts expect that Alexion Pharmaceuticals will post $5.41 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This story was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/alexion-pharmaceuticals-inc-alxn-rating-reiterated-by-morgan-stanley/1465463.html.

In related news, Director Bros. Advisors Lp Baker purchased 1,348,955 shares of the firm’s stock in a transaction that occurred on Wednesday, June 14th. The stock was acquired at an average price of $116.32 per share, for a total transaction of $156,910,445.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Ludwig Hantson purchased 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 14th. The shares were bought at an average price of $116.72 per share, with a total value of $1,167,200.00. Following the acquisition, the chief executive officer now directly owns 38,725 shares of the company’s stock, valued at approximately $4,519,982. The disclosure for this purchase can be found here. Insiders have purchased 2,019,734 shares of company stock valued at $235,606,846 in the last quarter. 4.35% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in ALXN. BlackRock Inc. increased its stake in shares of Alexion Pharmaceuticals by 2,689.8% in the first quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock valued at $2,258,467,000 after buying an additional 17,960,356 shares during the period. Vanguard Group Inc. increased its stake in shares of Alexion Pharmaceuticals by 3.1% in the first quarter. Vanguard Group Inc. now owns 14,467,456 shares of the biopharmaceutical company’s stock valued at $1,754,034,000 after buying an additional 433,293 shares during the period. State Street Corp increased its stake in shares of Alexion Pharmaceuticals by 6.8% in the first quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock valued at $1,369,846,000 after buying an additional 718,756 shares during the period. Jennison Associates LLC increased its stake in shares of Alexion Pharmaceuticals by 15.8% in the first quarter. Jennison Associates LLC now owns 9,622,914 shares of the biopharmaceutical company’s stock valued at $1,166,682,000 after buying an additional 1,309,529 shares during the period. Finally, Ameriprise Financial Inc. increased its stake in shares of Alexion Pharmaceuticals by 8.0% in the first quarter. Ameriprise Financial Inc. now owns 6,149,572 shares of the biopharmaceutical company’s stock valued at $745,579,000 after buying an additional 454,069 shares during the period. Institutional investors and hedge funds own 94.37% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

The Fly

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.